

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

DEC 14 2004

(use as many sheets as necessary)

## Complete if Known

Application Number	10/618,444
Filing Date	July 11, 2003
First Named Inventor	Julie K. Andersen
Group Art Unit	1642
Examiner Name	Unassigned
Attorney Docket Number	314-300710US
Date Submitted	December 8, 2004

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
DK	1	5,206,226		Sabin	4/27/1993	
	2	5,906,996		Murphy	5/25/1999	
	3	6,417,177		Nelson	7/9/2002	
	4	6,573,257		Malfroy-Camine et al.	7/3/2003	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
DK	5	Adams and Odunze (1991) <i>Free Radic Biol. Med.</i> 10, 161-169	
	6	Andersen, J.K. (2001) Pp. 11-25 In: <i>Ageing Vulnerability: Causes and Interventions</i> , Novartis	
	7	Foundation Symposium 235, John Wiley and Sons, Inc	
	8	Beal (1992) <i>Ann. Neurol.</i> 31: 119-130	
	9	Ben-Shachar <i>et al.</i> (1991) <i>J. Neurochem.</i> , 56(4): 1441-1444	
	10	Berg <i>et al.</i> (2001) <i>J. Neurochem.</i> 79: 225-236	
	11	Bush and Masters (2001) <i>Science</i> 292: 2251-2252	
	12	Castellani <i>et al.</i> (2000) <i>Proc. Natl. Acad. Sci. USA</i> 98: 14669-14674	
	13	Cherny <i>et al.</i> (2001) <i>Neuron</i> 30: 665-676	
	14	Connor <i>et al.</i> (1995) <i>J. Neurochem.</i> 65: 717-724	
	15	Connor <i>et al.</i> (2001) <i>Pediatr. Neurol.</i> 25: 118-129	
	16	Cozzi <i>et al.</i> (2000) <i>J. Biol. Chem.</i> 275: 25122-25129	

Examiner  
SignatureDate  
Considered

12/12/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)	Substitute for form 1449A-8/PTO		Complete if Known	
	Application Number	10/618,444		
	Filing Date	July 11, 2003		
	First Named Inventor	Julie K. Andersen		
	Group Art Unit	1642		
	Examiner Name	Unassigned		
	Attorney Docket Number	314-300710US		
	Date Submitted	December 8, 2004		

DK	17	Curtis <i>et al.</i> (2001) <i>Nat. Genet.</i> 28: 350-354	
	18	Dexter <i>et al.</i> (1987) <i>Lancet</i> 21: 1219-1220	
	19	Dexter <i>et al.</i> (1989) <i>J. Neurochem.</i> 52: 1830-1836	
	20	Du <i>et al.</i> (2001) <i>Proc. Natl. Acad. Sci. USA</i> 98: 14669-14674	
	21	Galvani <i>et al.</i> (1995) <i>Toxic In Vitro</i> , 9(4): 365-368	
	22	Gassen <i>et al.</i> (1997) <i>Pharmacol., &amp; Toxicol.</i> , 80: 159-166	
	23	Gerlach <i>et al.</i> (1994) <i>J. Neurochem.</i> 63:793-807	
	24	Griffiths <i>et al.</i> (1999) <i>Brain</i> 122: 667-673	
	25	Gutteridge (1992) <i>Ann. Neurol.</i> 32: S16-S21	
	26	Han <i>et al.</i> (2000) <i>Cell Mol. Biol.</i> 46: 517-528	
	27	Harrison and Arosio (1996) <i>Biochim. Biophys. Acta</i> 1275: 161-203	
	28	Huang <i>et al.</i> (1999) <i>J. Biol. Chem.</i> 274: 37111-37116	
	29	Kato, <i>et al.</i> (2001) <i>Am. J. Hum. Genet.</i> 69: 191-197	
	30	Kaur and Andersen (2002) <i>Aging Cell.</i> 1(1): 17-21	
	30	Kaur and Andersen (2004) <i>Ageing Res Rev.</i> 3(3): 327-43	
	32	Kaur <i>et al.</i> (2003) <i>Neuron.</i> 37(6): 889-890.	
	33	Kidani <i>et al.</i> (1974) <i>Jap. Analyst</i> 23, 1375-1378	
	34	Lan and Jiang (1997) <i>J. Neural Transm.</i> 104: 649-660	
	35	Marciani <i>et al.</i> (1991) <i>Haematologica</i> 76: 131-134	
	36	Orino <i>et al.</i> (2001) <i>Biochem. J.</i> 357: 241-247	
	37	Porter and Huehns (1989) <i>Baillieres Clin. Haematol.</i> 2: 459-474	
	38	Sofic <i>et al.</i> (1988) <i>J. Neural. Transm.</i> 74: 199-205	
	39	Sofic <i>et al.</i> (1991) <i>J. Neurochem.</i> 56: 978-982	
✓	40	Thompson <i>et al.</i> (2001) <i>Brain Res. Bull.</i> 55: 155-164	


Examiner Signature		Date Considered	12/12/05
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)	Complete if Known	
	Application Number	10/618,444
	Filing Date	July 11, 2003
	First Named Inventor	Julie K. Andersen
	Group Art Unit	1642
	Examiner Name	Unassigned
	Attorney Docket Number	314-300710US
	Date Submitted	December 8, 2004

DK	41	Yantiri and Andersen (1999) <i>IUBMB Life</i> 48: 1-3	
1	42	Yassin, <i>et al.</i> (2000) <i>J. Neurol. Sci.</i> 173: 40-44	
↓	43	Yoshida <i>et al.</i> (2001) <i>J. Synchrotron Radiat.</i> 8: 998-1000	
✓	44	Youdim <i>et al.</i> (1993) <i>Mov. Dis.</i> 8: 1-12	

Examiner Signature		Date Considered	12/12/03
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/618,444
Filing Date	July 11, 2003
First Named Inventor	Julie K. Andersen
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	314-300710US
Date Submitted	May 10, 2004

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
DK	1	5,980,914		Gerolymatos	11/9/1999	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
DK	2	BEN-SHACHAR ET AL. (1991) "The Iron Chelator Desferrioxamine (Desferal) Retards 6-Hydroxydopamine-Induced Degeneration of Nigrostriatal Dopamine Neurons" Journal of Neurochemistry, Vol. 56, No. 4, pp. 1441-1444	
↓	3	GALVANI ET AL. (1995) "Mitochondrial Toxicity of Iron and the Protective Role of Ferritin on Dopaminergic PC12 Cell Line" Toxic In Vitro Vol.9, No. 4, pp. 365-368	
↓	4	GASSEN ET AL. (1997) "The Potential Role in Iron Chelators in the Treatment of Parkinson's Disease and Related Neurological Disorders" Pharmacology & Toxicity Vol. 80, pp. 159-166	

Examiner Signature		Date Considered	12/12/03
-----------------------	---	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.